Allarity Therapeutics, Inc. Increase (Decrease) in Accounts Payable
Allarity Therapeutics, Inc. (ALLR) reported Increase (Decrease) in Accounts Payable of -$169.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayable · last filed 2026-08-14
- Allarity Therapeutics, Inc. increase (decrease) in accounts payable for the quarter ending 2026-06-30 was -$122.00K, a 147.10% decline year-over-year.
- Allarity Therapeutics, Inc. increase (decrease) in accounts payable for the quarter ending 2026-03-31 was -$47.00K, a 126.55% decline year-over-year.
- Allarity Therapeutics, Inc. increase (decrease) in accounts payable for the quarter ending 2025-12-31 was -$1.57M.
- Allarity Therapeutics, Inc. increase (decrease) in accounts payable for the quarter ending 2025-09-30 was -$3.00K.
- Allarity Therapeutics, Inc. increase (decrease) in accounts payable for fiscal 2025 was -$1.14M.
- Allarity Therapeutics, Inc. increase (decrease) in accounts payable for fiscal 2024 was -$4.11M, a 289.75% decline from fiscal 2023.
- Allarity Therapeutics, Inc. increase (decrease) in accounts payable for fiscal 2023 was $2.17M, a 65.12% decline from fiscal 2022.
- Allarity Therapeutics, Inc. increase (decrease) in accounts payable for fiscal 2022 was $6.21M.
| Period end | Increase (Decrease) in Accounts Payable 3 month | Increase (Decrease) in Accounts Payable 6 month | Increase (Decrease) in Accounts Payable 9 month | Increase (Decrease) in Accounts Payable 9 month as first filed | Increase (Decrease) in Accounts Payable 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | -$122.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | -$169.00K 10-Q · filed 2026-08-14 | -$1.74M derived: sum of 3 quarters · filed 2026-08-14 | -$1.74M derived: sum of 4 quarters · filed 2026-08-14 | |
| 2026-03-31 | -$47.00K 10-Q · filed 2026-05-15 | -$1.62M derived: sum of 2 quarters · filed 2026-05-15 | -$1.62M derived: sum of 3 quarters · filed 2026-05-15 | -$1.36M derived: sum of 4 quarters · filed 2026-08-14 | |
| 2025-12-31 | -$1.57M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | -$1.57M derived: sum of 2 quarters · filed 2026-03-30 | -$1.32M derived: sum of 3 quarters · filed 2026-08-14 | -$1.14M 10-K · filed 2026-03-30 | |
| 2025-09-30 | -$3.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $256.00K derived: sum of 2 quarters · filed 2026-08-14 | $433.00K 10-Q · filed 2025-11-14 | -$52.00K derived: sum of 4 quarters · filed 2026-08-14 | |
| 2025-06-30 | $259.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $436.00K 10-Q · filed 2026-08-14 | -$49.00K derived: sum of 3 quarters · filed 2026-08-14 | -$3.10M derived: sum of 4 quarters · filed 2026-08-14 | |
| 2025-03-31 | $177.00K 10-Q · filed 2026-05-15 | -$308.00K derived: sum of 2 quarters · filed 2026-05-15 | -$3.36M derived: sum of 3 quarters · filed 2026-05-15 | -$6.77M derived: sum of 4 quarters · filed 2026-05-15 | |
| 2024-12-31 | -$485.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | -$3.54M derived: sum of 2 quarters · filed 2026-03-30 | -$6.95M derived: sum of 3 quarters · filed 2026-03-30 | -$4.11M 10-K · filed 2026-03-30 | |
| 2024-09-30 | -$3.05M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | -$6.46M derived: sum of 2 quarters · filed 2025-11-14 | -$3.62M 10-Q · filed 2025-11-14 | -$1.55M derived: sum of 4 quarters · filed 2025-11-14 | |
| 2024-06-30 | -$3.41M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-15 | -$573.00K 10-Q · filed 2025-08-15 | $1.50M derived: sum of 3 quarters · filed 2025-08-15 | -$246.00K derived: sum of 4 quarters · filed 2025-08-15 | |
| 2024-03-31 | $2.84M 10-Q · filed 2025-05-09 | $4.91M derived: sum of 2 quarters · filed 2025-05-09 | $3.17M derived: sum of 3 quarters · filed 2025-05-09 | $4.80M derived: sum of 4 quarters · filed 2025-05-09 | |
| 2023-12-31 | $2.07M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $327.00K derived: sum of 2 quarters · filed 2025-03-31 | $1.97M derived: sum of 3 quarters · filed 2025-03-31 | $2.17M 10-K · filed 2025-03-31 | |
| 2023-09-30 | -$1.74M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | -$102.00K derived: sum of 2 quarters · filed 2024-11-14 | $96.00K 10-Q · filed 2024-11-14 | $1.82M derived: sum of 4 quarters · filed 2024-11-14 | |
| 2023-06-30 | $1.64M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-05 | $1.84M 10-Q · filed 2024-08-05 | $3.56M derived: sum of 3 quarters · filed 2024-08-05 | $2.87M derived: sum of 4 quarters · filed 2024-08-05 | |
| 2023-03-31 | $198.00K 10-Q · filed 2024-05-14 | $1.92M derived: sum of 2 quarters · filed 2024-05-14 | $1.23M derived: sum of 3 quarters · filed 2024-05-14 | $1.37M derived: sum of 4 quarters · filed 2024-05-14 | |
| 2022-12-31 | $1.72M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-08 | $1.03M derived: sum of 2 quarters · filed 2024-03-08 | $1.17M derived: sum of 3 quarters · filed 2024-03-08 | $6.21M 10-K · filed 2024-03-08 | |
| 2022-09-30 | -$692.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | -$553.00K derived: sum of 2 quarters · filed 2023-11-14 | $4.48M 10-Q · filed 2023-11-14 | $4.55M derived: sum of 4 quarters · filed 2023-11-14 | |
| 2022-06-30 | $139.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | $5.17M 10-Q · filed 2023-08-14 | $5.24M derived: sum of 3 quarters · filed 2023-08-14 | $3.64M derived: sum of 4 quarters · filed 2023-08-14 | |
| 2022-03-31 | $5.04M 10-Q · filed 2023-05-11 | $5.10M derived: sum of 2 quarters · filed 2023-05-11 | $3.50M derived: sum of 3 quarters · filed 2023-05-11 | $3.62M derived: sum of 4 quarters · filed 2023-05-11 | |
| 2021-12-31 | $67.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-13 | -$1.53M derived: sum of 2 quarters · filed 2023-03-13 | -$1.42M derived: sum of 3 quarters · filed 2023-03-13 | -$1.31M 10-K · filed 2023-03-13 | |
| 2021-09-30 | -$1.60M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | -$1.49M derived: sum of 2 quarters · filed 2022-11-14 | -$1.38M 10-Q · filed 2022-11-14 | -$1.38M 10-Q · filed 2021-11-23 | -$1.04M derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | $114.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-10-07 | $222.00K 10-Q · filed 2022-10-07 | $556.00K derived: sum of 3 quarters · filed 2022-10-07 | ||
| 2021-03-31 | $108.00K 10-Q · filed 2022-05-27 | $442.00K derived: sum of 2 quarters · filed 2022-05-27 | |||
| 2020-12-31 | $334.00K derived: 10-K 12 month − 10-Q/A 9 month · filed 2022-05-17 | -$62.00K 10-K · filed 2022-05-17 | |||
| 2020-09-30 | -$396.00K 10-Q/A · filed 2022-05-17 | -$395.00K 10-Q · filed 2021-11-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |
| Pasithea Therapeutics Corp. (KTTA) | United States | $0.017B | -0.81 |
| Biofrontera Inc. (BFRI) | United States | $0.018B | -2.13 |
| Korsana Biosciences, Inc. (CYCN) | United States | $0.016B | |
| Citius Pharmaceuticals, Inc. (CTXR) | United States | $0.016B | -133.06 |
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| Lantern Pharma Inc. (LTRN) | United States | $0.015B | -2.87 |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| Anebulo Pharmaceuticals, Inc. (ANEB) | United States | $0.015B |